## SEC Form 4

Π

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

#### OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1	Address of Reporting EOFFREY F	Person <sup>*</sup>	2. Issuer Name and Ticker or Trading Symbol <u>NABI BIOPHARMACEUTICALS</u> [ NABI ]		tionship of Reporting P all applicable) Director	erson(s) to Issuer 10% Owner	
	(First) BIOTHERAPEUTI	(Middle) ICS, INC.	3. Date of Earliest Transaction (Month/Day/Year) 05/20/2010	-	Officer (give title below)	Other (specify below)	
	SING BLVD.		4. If Amendment, Date of Original Filed (Month/Day/Year)	Line)	vidual or Joint/Group Filing (Check Applicable		
(Street)				X	Form filed by One Re	eporting Person	
FRAMINO	GHAM MA	01702			Form filed by More th Person	nan One Reporting	
(City)	(State)	(Zip)					

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	if any	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	Form: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130. 4)
Common Stock	05/20/2010		<b>P</b> <sup>(1)</sup>		1,908	Α	\$5.24	25,679	D	

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$5.24	05/20/2010		A		40,000		(2)	05/20/2017	Common Stock	40,000	\$0	40,000	D	

### Explanation of Responses:

1. The purchase reported in this form was made upon election of director to receive a portion of his annual director fee retainer in common stock pursuant to Section 14 of the 2007 Omnibus Equity and Incentive Plan.

2. The Stock Option (right to buy) is exercisable in four equal installments on August 20, 2010, November 20, 2010, February 20, 2011, and May 20, 2011. **Remarks:** 

> James E. Dawson, as attorneyin-<u>fact</u>

05/24/2010

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.